Results 211 to 220 of about 26,531 (270)
Cognitive Sarcopenia: Prevalence and the Risk for Mortality and Healthy Aging in the KORA‐Age Study
ABSTRACT Background Cognitive sarcopenia, defined by this study as the co‐existence of sarcopenia and cognitive impairment, has been frequently reported in older adults, while we hypothesize that the co‐existence increases the risk for adverse outcomes in the older general population.
Marie‐Theres Huemer +4 more
wiley +1 more source
Polygonum cognatum extracts exhibit strong antioxidant, anti‐inflammatory, antidiabetic, and antimicrobial activities. This study demonstrates, for the first time, histone deacetylase inhibitory activity, revealing epigenetic modulation potential.
Serhat Karaman +2 more
wiley +1 more source
CASE REPORT - Bereitschaftspotential in Tic Disorders : A Preliminary Observation
Harpreet S. Duggal, S. Haque Nizamie
openalex +1 more source
Summary Introduction Peri‐operative neurocognitive disorders are common among older adults presenting for surgery and anaesthesia. Cognitive screening is recommended to identify patients at risk for adverse neurocognitive outcomes, though the most appropriate peri‐operative tool remains debated.
Kelly J. Atkins +6 more
wiley +1 more source
New Tic Disorder in a Child With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor. [PDF]
Duehlmeyer SR, Elson EC, Oermann CM.
europepmc +1 more source
ABSTRACT Immune checkpoint regulators can improve neurological functions in Alzheimer's disease. However, it remains blurred whether these regulators may ameliorate temporal lobe epilepsy (TLE) and TLE‐related cognitive impairment. This study analyzed the bulk transcriptomic data of human TLE hippocampi by bioinformatics.
Man Li +3 more
wiley +1 more source
Integrating transdiagnostic and holistic approaches in early neurodevelopmental screening
Developmental Medicine &Child Neurology, Volume 68, Issue 3, Page 305-306, March 2026.
Kahoko Yasumitsu‐Lovell
wiley +1 more source
The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications
ABSTRACT Ecopipam is a first‐in‐class dopamine D1 receptor antagonist under investigation for the treatment of Tourette syndrome. This open‐label, fixed‐sequence, three‐cohort study evaluated whether ecopipam induces or inhibits cytochrome P450 (CYP) 1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4, organic anion‐transporting polypeptide (OATP) 1B1, and p ...
Virginia D. Schmith +4 more
wiley +1 more source

